CA3045024A1 - Natural combination hormone replacement formulations and therapies - Google Patents

Natural combination hormone replacement formulations and therapies Download PDF

Info

Publication number
CA3045024A1
CA3045024A1 CA3045024A CA3045024A CA3045024A1 CA 3045024 A1 CA3045024 A1 CA 3045024A1 CA 3045024 A CA3045024 A CA 3045024A CA 3045024 A CA3045024 A CA 3045024A CA 3045024 A1 CA3045024 A1 CA 3045024A1
Authority
CA
Canada
Prior art keywords
estradiol
progesterone
subject
auc
estrone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3045024A
Other languages
English (en)
French (fr)
Inventor
Julia M. Amadio
Brian A. Bernick
Sebastian Mirkin
Original Assignee
TherapeuticsMD Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TherapeuticsMD Inc filed Critical TherapeuticsMD Inc
Publication of CA3045024A1 publication Critical patent/CA3045024A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3045024A 2016-12-05 2017-12-05 Natural combination hormone replacement formulations and therapies Abandoned CA3045024A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662430339P 2016-12-05 2016-12-05
US62/430,339 2016-12-05
US201762481060P 2017-04-03 2017-04-03
US62/481,060 2017-04-03
PCT/US2017/064788 WO2018136161A1 (en) 2016-12-05 2017-12-05 Natural combination hormone replacement formulations and therapies

Publications (1)

Publication Number Publication Date
CA3045024A1 true CA3045024A1 (en) 2018-07-26

Family

ID=62908279

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3045024A Abandoned CA3045024A1 (en) 2016-12-05 2017-12-05 Natural combination hormone replacement formulations and therapies

Country Status (11)

Country Link
EP (1) EP3548036A4 (cg-RX-API-DMAC10.html)
JP (1) JP2020504093A (cg-RX-API-DMAC10.html)
KR (1) KR20200018383A (cg-RX-API-DMAC10.html)
CN (1) CN110290793A (cg-RX-API-DMAC10.html)
AU (1) AU2017394679A1 (cg-RX-API-DMAC10.html)
BR (1) BR112019011655A2 (cg-RX-API-DMAC10.html)
CA (1) CA3045024A1 (cg-RX-API-DMAC10.html)
IL (1) IL267023A (cg-RX-API-DMAC10.html)
MX (1) MX2019006513A (cg-RX-API-DMAC10.html)
RU (1) RU2019115913A (cg-RX-API-DMAC10.html)
WO (1) WO2018136161A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220105107A1 (en) * 2020-10-01 2022-04-07 Michael Liguori Bioidentical progesterone cream infused with nanoemulsified cbd

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202316026D0 (en) * 2023-10-19 2023-12-06 Theramex Hq Uk Ltd Methods of prevention or treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208225A (en) * 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US6901278B1 (en) * 2002-01-29 2005-05-31 Morris Notelovitz Methods for reducing the risk of breast cancer in and improving the health of women
US20040062794A1 (en) * 2002-09-30 2004-04-01 Lee Shulman 17Beta- estradiol/levonorgestrel transdermal patch for hormone replacement therapy
US9301920B2 (en) * 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
AR100562A1 (es) * 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220105107A1 (en) * 2020-10-01 2022-04-07 Michael Liguori Bioidentical progesterone cream infused with nanoemulsified cbd

Also Published As

Publication number Publication date
IL267023A (en) 2019-07-31
RU2019115913A (ru) 2021-01-15
AU2017394679A1 (en) 2019-06-13
WO2018136161A1 (en) 2018-07-26
WO2018136161A9 (en) 2019-08-22
EP3548036A4 (en) 2020-06-17
RU2019115913A3 (cg-RX-API-DMAC10.html) 2021-03-19
KR20200018383A (ko) 2020-02-19
MX2019006513A (es) 2019-08-14
JP2020504093A (ja) 2020-02-06
CN110290793A (zh) 2019-09-27
BR112019011655A2 (pt) 2019-10-22
EP3548036A1 (en) 2019-10-09

Similar Documents

Publication Publication Date Title
US20180221389A1 (en) Natural combination hormone replacement formulations and therapies
Burrows et al. The effects of hormonal contraceptives on female sexuality: a review
US10806740B2 (en) Natural combination hormone replacement formulations and therapies
US20190247401A1 (en) Natural combination hormone replacement formulations and therapies
US11103513B2 (en) Natural combination hormone replacement formulations and therapies
Sibai et al. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra™/Evra™)
Ruggiero et al. Estrogen: physiology, pharmacology, and formulations for replacement therapy
Winkler et al. The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters
Skouby et al. A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 μg ethinyl estradiol combined with 100 μg levonorgestrel
Jensen Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest
JP2010180236A (ja) 妊娠を防ぎ、月経前総合的症状を減少させるための経口避妊薬
JP7827774B2 (ja) 月経困難症治療用組成物
Frisendahl et al. The clinical relevance of having more than one estrogen in combined hormonal contraception to address the needs of women
Borgelt et al. Estradiol valerate/dienogest: a novel combined oral contraceptive
WO2018136161A9 (en) Natural combination hormone replacement formulations and therapies
Utian et al. Relief of hot flushes with new plant-derived 10-component synthetic conjugated estrogens
Akintomide et al. Nomegestrol acetate/17-beta estradiol: a review of efficacy, safety, and patient acceptability
US20230302015A1 (en) Natural combination hormone replacement formulations and therapies
AU2016366200B2 (en) Vaginal inserted estradiol pharmaceutical compositions and methods
Kolitz et al. Strontium citrate associated drug reaction with eosinophilia and systemic symptoms syndrome with granulomatous dermatitis
Onishi et al. Hormonal and complimentary treatments for endometriosis: a narrative review
Davis et al. Drugs for the treatment of menopausal symptoms
WO2020081726A1 (en) Methods of treating menopausal symptoms using low dose progesterone
Rybacki HOW SUPPLIED

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20240318